CLTC and neoplasm: Consistent with this, we found that the Cltc CD4+ T cell epitope could be replaced by PADRE(X) when tethered to the CD8+ T cell minimal epitope (Mut_48.10) in a vaccine/PD-1 blockade therapeutic combination regimen and still result in complete tumor rejection (Figure 11B).